Background: Radical surgery provides the best chance of cure for adrenocortical carcinoma (ACC), but perioperative surgical care for these patients is yet to be standardized. Methods: A working group appointed jointly by ENSAT and ESES used Delphi methodology to produce evidence-based recommendations for the perioperative surgical care of patients with ACC. Papers were retrieved from electronic databases. Evidence and recommendations were classified according to the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system, and were discussed until consensus was reached within the group. Results: Twenty-five recommendations for the perioperative surgical care of patients with ACC were formulated. The quality of evidence is low owing to the rarity of the disease and the lack of prospective surgical trials. Multi-institutional prospective cohort studies and prospective RCTs are urgently needed and should be strongly encouraged. Conclusion: The present evidence-based recommendations provide comprehensive advice on the optimal perioperative care for patients undergoing surgery for ACC.
Introduction
Adrenocortical carcinoma (ACC) is a rare and highly aggressive malignancy. Interest in this condition has increased in recent years 1, 2 , and the first international multicentre RCTs on chemotherapy in advanced ACC were published in 2012 3 and 2015 4 . There is a consensus that surgery provides the best chance of cure for patients with ACC, but evidence-based protocols are lacking as the small number of patients operated on in each hospital, and the complex challenges related to the operations, have hampered attempts to standardize the surgical management of these tumours. In this context, a collaborative working group was appointed as a joint initiative from terms: 'adrenocortical cancer', 'adrenocortical carcinoma', 'adrenal cancer', 'adrenal carcinoma' and 'adrenal surgery'. Only studies published in English were included. Cross-checks for further publications were made based on reviews written by members of ESES 9 , reviews from the European Society of Medical Oncology (ESMO) 10 and other recent reviews 2, 11 . The invited experts defined the questions to be addressed and subsequently issued a draft consensus statement. Key single-sentence statements were taken from this document and circulated to all members for anonymous online voting. Statements with at least 80 per cent agreement were considered to have reached consensus and to be strong. Statements with less than 80 per cent agreement were reported to have achieved low consensus and were forwarded for discussion at the second consensus meeting held in November 2014. After further rounds of e-mail communication, agreement was reached for all statements.
The quality of evidence and strength of recommendations were categorized according to the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system 12 -14 . When recommendations were rated as 'strong', the phrase 'the panel recommends' was used (indicating that the panel is confident that the desirable effects of adherence to a recommendation outweigh the undesirable effects). When recommendations were rated as 'weak', the phrase 'the panel suggests' was used (indicating that the desirable effects of adherence to a recommendation most likely outweigh the undesirable effects, but the panel is less confident).
The quality of evidence was rated as 'high' (further research is very unlikely to change the panel's confidence in the estimate of the effect), 'moderate' (further research is likely to have an important impact on the panel's confidence in the estimate of the effect and may change the estimate), 'low' (further research is very likely to have an important impact on the panel's confidence in the estimate of the effect and is likely to change the estimate) or 'very low' (any estimate of the effect is very uncertain).
The level of evidence and final recommendations were evaluated and adjusted until consensus was achieved. The evidence is presented in the text, and the recommendations are summarized in Table 1 . 
Cross-sectional imaging
The goals of preoperative imaging are as follows: to determine whether an adrenal mass is at increased risk of being an ACC (see also Definition of an adrenal mass at increased risk of malignancy, below); and to plan the surgical procedure. Thoracoabdominal CT with contrast injection provides information regarding the size, shape, margins, internal structure, vascular distribution, venous thrombus, lymph node involvement, adjacent organ invasion (of kidney, distal pancreas, spleen, liver or diaphragm), the presence of intravascular thrombus in the inferior vena cava (IVC) or left renal vein, and distant spread of tumours 16, 18, 26 . Usually, ACCs are large at presentation, with a diameter greater than 6 cm in more than 90 per cent of patients 16, 26 . The median size reported in large series is 10-11 (range 240) cm, whereas most benign adrenal tumours are usually smaller than 5 cm 16 . Non-enhanced CT usually identifies a heterogeneous but well defined suprarenal mass that displaces adjacent organs 16 . A spontaneous density of more than 10 Hounsfield units (HU) has a high sensitivity, but relatively low specificity to define an adrenal mass as malignant 16, 26, 27 . After contrast injection, the periphery typically shows greater enhancement with relatively low central enhancement owing to areas of haemorrhage and necrosis. In contrast to benign lesions, ACCs retain intravenously administered contrast materials and exhibit slow washout after administration, with relative and absolute percentages of less than 40 and 50 per cent respectively at 10 min, or 40 and 60 per cent respectively at 15 min 26 . Calcifications (small punctate or coarse) are relatively common, and usually located centrally 16, 26 . Vascular invasion with a thrombus extending within the left renal vein and/or IVC is not uncommon (9-19 per cent of patients), and occurs more often in right-sided ACCs 16, 26 . Metastases are frequently found at presentation; the most common sites are regional or para-aortic/paracaval lymph nodes (25-46 per cent), lung (45-97 per cent), liver (48-96 per cent) and bone (11-33 per cent) 18 .
MRI with gadolinium enhancement and chemical-shift MRI can further characterize ACCs, with high sensitivity and specificity. Magnetic resonance angiography is superior to CT in the diagnosis of venous tumoral thrombus or venous invasion 16, 28 . The typical feature of ACC is a heterogeneous mass owing to haemorrhage and foci of necrosis. On T1-weighted imaging, ACCs are isointense or hypointense compared with liver parenchyma. On T2-weighted imaging, ACCs appear hyperintense compared with liver, with a heterogeneous texture. Contrast enhancement is generally avid with slow wash-out 16, 28 .
Recommendation 3
The 29, 30 . The specificity of 18 FDG-PET is lowered by the fact that the tracer is also actively taken up by some benign adrenal neoplasms and phaeochromocytomas. However, the most important ability of PET is to detect distant metastasis, which makes it a valuable tool in the staging and follow-up of patients with ACC undergoing treatment 29, 30 .
A 
Recommendation 4
The panel recommends 18 FDG-PET within a maximum of 6 weeks before adrenalectomy for suspected ACC.
Agreement: Strong Recommendation grade: Weak Evidence level: Low

Definition of an adrenal mass at increased risk of malignancy
Adrenal incidentalomas are the most common adrenal disorder 34 -36 . They encompass a wide spectrum of lesions, the vast majority of which are benign 36 -38 . Based on various recommendations 37,39 -41 , surgical resection is required only for secreting tumours, symptomatic lesions and atypical large lesions with significant risk of malignancy.
The suspicion of malignancy is driven mainly by tumour size, intratumoral radiological signs of malignancy, signs of local invasion or distant metastasis, and type of hormonal secretion.
The risk of malignancy increases with tumour size and becomes significant for lesions larger than 4 cm. Intratumoral radiological signs of malignancy include the following: spontaneous density above 10 HU; signal loss on chemical-shift imaging below 20 per cent on MRI; high 18 FDG-PET uptake, low central enhancement due to areas of haemorrhage and necrosis, and slow wash-out after intravenous injection of contrast material.
Tumours secreting androgen, oestrogen, steroid precursors or multiple hormones are more likely to be malignant.
An adrenal biopsy is of very limited value for the evaluation of adrenal neoplasms, except for very rare primary adrenal lymphoma or when trying to demonstrate metastatic disease. Furthermore, biopsy can be dangerous in phaeochromocytomas and ACCs 42 ; therefore, adrenal biopsy should be avoided.
Recommendation 5
The Recommendations for the surgical approach to nonmetastatic primary adrenocortical carcinoma are summarized in Fig. 1 . It is important to note that in many patients the ACC diagnosis is confirmed only after surgery; hence the surgical strategy is based on a supposed diagnostic procedure.
Management in referral centres
Surgeons and their training, as well as the volume of the hospital, have a positive effect on postoperative morbidity/mortality and long-term survival for various types of cancer 43 -45 , including those for pancreatic cancer 46 , rectal cancer 47, 48 , liver cancer 46 and oesophageal cancer 49 . For adrenal surgery, surgeons with a higher caseload have a higher rate of R0 resection 50 , and studies have highlighted the value of hospital or surgeon volume and the need for centralization irrespective of specialty practice 51 -53 . This is especially important because the widespread use of laparoscopic adrenalectomy has made surgical indications more liberal 54, 55 . For ACC surgery 56, 57 , the expertise of dedicated centres appears to have a positive impact on outcome, at least attributable to a multidisciplinary approach 58 , even though a recent large series 59 from the USA failed to demonstrate improved overall survival in patients treated more aggressively in high-volume centres.
Various cut-offs have been proposed to define expert centres, from four to ten adrenalectomies for ACC 56, 59 , or ten laparoscopic adrenalectomies 60 to 20 adrenalectomies per year 61 , but no strong conclusion can be drawn from the available evidence, and the definition of a high-volume centre is often controversial and culturally oriented.
The minimum consensus reached was that referral centres can be defined as those with surgeons who perform at least 15 adrenal procedures a year. A referral centre should at least have surgeons with expertise in both open and laparoscopic adrenal surgery, and with expertise (or available help if required) in vascular, hepatic or pancreatic resection. Within the referral centre, all patients should be discussed before surgery by a multidisciplinary team including surgeons, endocrinologists, oncologists, radiologists, pathologists, nuclear medicine physicians, biologists and geneticists.
Recommendation 7
The 
Oncological standards of adrenocortical cancer resection
Taking into account the aggressive behavior of ACC, the only chance for cure in patients without metastatic disease is complete primary tumour resection, avoiding violation of the tumour capsule or spillage of tumour cells, and achieving microscopically margin-free resection (R0) 62 -65 . Intraoperative tumour rupture or spillage and R2 resection are associated with very high recurrence rates and poor overall survival 66 -68 , and even R1 resection significantly diminishes the prognosis 67 . Because the ACC capsule can be thin or fibrotic, and the tumour itself often harbours softer and tighter parts, the resection of ACC should be performed with the utmost caution to avoid tumour spillage.
The anatomy of the upper retroperitoneum 69 70 .
To increase the number of patients amenable to R0 resection, some benefit of neoadjuvant chemotherapy (mitotane and etoposide or cisplatin-based chemotherapy) has been suggested recently for the treatment of patients with 'borderline' resectable adrenal tumours 71 . Nevertheless, in view of the low response rate to available chemotherapy 72 and the rapid growth of ACC, surgery first remains recommended if the lesion is amenable to R0 resection. This should be re-evaluated regularly according to the new therapeutic regimens.
Recommendation 8
Optimal surgical route: open versus laparoscopic approach
The standard surgical procedure for ACC is open surgery using a subcostal, midline or thoracoabdominal incision. It is widely accepted that open adrenalectomy is necessary for large malignant tumours invading the surrounding tissues (ENSAT stage III). Laparoscopic adrenalectomy can be considered for small tumours, and in experienced centres some advocate it as acceptable for tumours with diameter of 5-8 cm without invasion of adjacent organs (adrenal mass at increased risk of malignancy).
Owing to the low incidence of ACC, there are no randomized trials comparing laparoscopic and open approaches 73 , and current knowledge is based on retrospective studies and expert opinion 74 . In addition, most laparoscopic series published to date did not report long-term follow-up and included low numbers of patients 19,75 -83 . After the first report of a laparoscopic adrenalectomy by Gagner and colleagues in 1992 84 
The choice of the best surgical approach for ACC or suspected malignant adrenal mass should be based on both the size and evidence of local invasion. If a laparoscopic approach is considered for an adrenal tumour at increased risk of malignancy (a mass with radiological intratumoral signs of suspicion and without clear locoregional involvement), the procedure should be performed only for small lesions (reasonable cut-off of 6 cm) by highly experienced surgeons. The transperitoneal approach with the patient in the flank position might be preferred: first, because reported experience with the retroperitoneoscopic approach for ACC is very limited; second, because it might allow intraoperative assessment of the presence of distant metastasis; and, finally, because it might allow larger en bloc resection of the tumour. It is important to note that there is no evidence for the superiority of the transperitoneal approach in the literature.
If the adrenalectomy is performed laparoscopically, the principles of oncological surgery should be respected. As in the open approach, the laparoscopic procedure should include lymphadenectomy of the renal hilum. Because 30 per cent of preoperative stage II ACCs are upstaged to stage III after pathological examination, primarily due to microscopic invasion of the surrounding tissues 76 , the periadrenal fat has to be removed en bloc with the adrenal tumour 19 .
Considering the technical feasibility of laparoscopic adrenalectomy, tumour size is of major importance, and the risk of spillage or capsule rupture, even for benign tumours, appears to be higher if they are larger than 6 cm. This remains controversial, however, and some consider that for stage I/II ACCs smaller than 10 cm, the laparoscopic approach did not compromise the long-term oncological outcome as disease-specific and disease-free survival rates were comparable in the two groups 19 .
In the present authors' opinion, a size of less than 6 cm represents a reasonable cut-off for considering the laparoscopic approach for a suspected malignant adrenal mass, provided there is no invasion of adjacent organs and the procedure is performed by a highly experienced surgeon. When the likelihood of malignancy is high, the open approach is preferred. When involvement of the surrounding tissues is discovered, or there is a risk of spillage, capsule injury or incomplete resection, immediate conversion to an open approach must be done. Furthermore, any adverse intraoperative events should be reported in the operation notes, as this might lead to the discussion of an adjuvant therapy. 
Recommendation 10
The panel recommends the open approach as the standard of surgical care for confirmed or highly suspected ACC.
Agreement: Strong Recommendation grade: Strong Evidence level: Moderate
Recommendation 11
The panel does not recommend the laparoscopic approach for an adrenal mass with evidence of local invasion or suspected metastatic lymph nodes (ENSAT stage III).
Agreement: Strong
Role of regional lymphadenectomy
Retrospective data suggest that regional lymph node involvement in ACC has a negative impact on overall survival 67 and is frequently the cause of locoregional recurrence 85 -87 . As reported recently by Fassnacht et al. 70 , and independently validated in North America in the Surveillance, Epidemiology, and End Results (SEER) registries 88 , patients with stage III tumours and positive lymph nodes can have a 10-year overall survival rate of up to 40 per cent after resection, although this finding has been challenged recently 89 -91 . It is not yet decided whether a modified ENSAT classification should consider node-positive ACC as stage IV disease 89 .
Discrepant reports regarding lymph node involvement ranging from 4 to 73 per cent 65 -67,70,92,93 suggest that formal regional lymphadenectomy is neither formally performed by surgeons nor accurately assessed or reported by pathologists. According to large American and French series, approximately one-third of patients with ACC had formal lymphadenectomy as part of the tumour resection, reflecting the heterogeneity of operative management 65, 93 . However, pathological post-mortem studies of patients with ACC showed involvement of lymph nodes in approximately 70 per cent of patients 92 . Data from the German ACC Registry suggest a reduced risk of local recurrence and disease-related death if more than five lymph nodes are removed 94 . In addition, lymph node dissection contributes to more accurate tumour staging, but its influence on overall and disease-free survival is uncertain 91 . The precise determination of which lymphatic fields and how many nodes should be dissected remains to be elucidated.
The lymph nodes involved most frequently are those located in the renal hilum and the para-aortic/paracaval lymph nodes 95 . Periadrenal nodes 96 -103 , even if they are rarely found and involved, and nodes at the origin of the renal vessels 104 -106 should at least be sampled because they can be considered to be the first node stations of drainage 100 . If suspicious lymph nodes are observed on preoperative imaging, they should be removed to reduce the risk of local recurrence. More extended lymphadenectomy is an option because several pathways may be involved owing to tumour size or lymph node involvement.
Recommendation 14
Need for adjacent organ resection or extended resection
The upper limit of the perirenal space is not covered by Gerota's fascia, explaining the clinical finding that right-sided ACCs may invade the liver and/or diaphragm, and left-sided ACCs may invade the spleen, pancreas and/or diaphragm 69, 107 . Although published data offer sparse details about such intraoperative findings, it is generally agreed that adjacent organs should be resected en bloc if they are suspected to be invaded. This includes the spleen, distal pancreas, stomach, kidney, right liver, colon, diaphragm, and the wall of the IVC or left renal vein. The threshold for en bloc resection of adjacent organs, if they are suspected to be invaded, should be low.
To avoid the risk of capsular damage when dissecting the tumour from the kidney, some surgeons advocate performing en bloc resection of the retroperitoneal space including the kidney 65 , although a survival benefit of this radical approach has not been proven 64, 108 . A retrospective study 109 compared the oncological results of patients with stage II ACC treated by radical adrenalectomy alone or by nephroadrenalectomy. The results did not support the hypothesis that nephrectomy improved the oncological outcome. Combined nephrectomy, however, offers a lower risk of capsular rupture and can include complete lymphadenectomy of the renal hilum. In a multicentre European study 65 on surgery for ACC, pathological invasion of the kidney was observed in only 30 per cent of the patients with combined nephrectomy.
Extension of ACC to the adrenal, renal vein or IVC occurs in approximately 25 per cent of the patients 110, 111 . Venous involvement consists mostly of intravenous tumour thrombus, but can be associated with direct vascular invasion. Thrombectomy may require IVC cross-clamping above or below the hepatic vein confluence or cardiopulmonary bypass, depending on the upper level of the thrombus 111 . The resection should include complete thrombectomy, a flush manoeuvre and, occasionally, vascular cuff or prosthetic IVC replacement. A 3-year overall survival rate of 25-29 per cent in a large series encourages the performance of a venous resection in the presence of IVC or renal vein invasion 110, 112 .
Recommendation 16
The panel recommends extended en bloc multivisceral resection of the invaded adjacent organ(s) to avoid tumour rupture or spillage for stage III ACC.
Agreement: Strong
Recommendation grade: Strong Evidence level: Moderate
Recommendation 17
The panel cannot recommend routine resection of the ipsilateral kidney in the absence of direct renal invasion.
Agreement: Strong
Recommendation grade: Weak Evidence level: Low
Quality criteria for operation notes and pathological reports for ACC
Operation note
In the future, outcome analysis will have to be based on more accurate records of the extent and type of operation performed for each patient with a suspected or confirmed diagnosis of ACC. It can be anticipated that use of a standardized operating note could summarize perioperative information considered to be significant for future clinical studies. It is expected that a standardized operation note could be developed further to a point where the data fields could be incorporated into multicentre databases (such as Eurocrine or ENSAT). The minimum information to be filed is summarized in Table 2 (an example of a standardized operation note is included in Fig. S1 , supporting information).
Recommendation 18
The panel recommends that an operation note should be standardized with detailed preoperative and surgical information ( 
Pathology report
The standards for reporting ACCs, as developed for example by the Royal College of Pathologists (available for download at https://www.rcpath.org/resourceLibrary/ g109_adrenaldataset_jan12-pdf.html) or the French practice guidelines issued by the COMETE group (http:// sfendocrino.org/article/599/recommandations) were used to make these comments and recommendations 113 .
The request form that accompanies the specimen should include: clinical details (clinical syndrome and any history of familial disease (for example, multiple endocrine neoplasia type 1 or Li-Fraumeni syndrome); any significant intraoperative events (such as tumour rupture and sutures marking the adrenal vein or areas of the tumour where margins might have been compromised); if the operation was performed laparoscopically, a statement should be made about intraoperative fragmentation of the tumour, which is very difficult to assess retrospectively by the pathologist. Indeed, removal of the specimen in a laparoscopic bag may lead to tumour disruption that compromises the assessment of tumour size, integrity of the tumour capsule and completeness of the excision.
The histological diagnosis of adrenal tumours remains challenging. If adrenocortical origin of the tumour remains debatable, expression of SF1 is the most valid marker 114, 115 . From a surgical perspective, the minimum information needed in the pathological report includes: the integrity of the tumour capsule, and the presence or absence of invasion into periadrenal soft tissues and adjacent organs (to be noted separately). If the normal adrenal gland can be identified, its relationship to the tumour and its appearance must be noted. The adrenal vein should be sampled to determine whether tumour thrombus is present (this is especially important in specimens with an attached kidney). The number of lymph nodes submitted or identified in the main specimen must be recorded. A clear statement must be made as to whether the resection status is R0, R1 or R2, because this parameter has a strong influence on predicted 5-year survival (50, 20 or 15 per cent respectively) 67 .
The modified staging system introduced by ENSAT 70 must be used, including the modified definition for stage III (a tumour with any one of the following: positive lymph nodes, extra-adrenal tissue infiltration, or venous tumour thrombus in renal vein/IVC) and stage IV (any tumour with distant metastasis) tumours. The prognostic value of the ENSAT classification (Table S2 , supporting information) was demonstrated recently in a large SEER cohort 88 . Weiss score 116 (Table S3 , supporting information) and Ki-67 proliferation index must be recorded.
Recommendation 19
The The risk of recurrence after surgery is influenced mainly by ENSAT stage, R resection status and Ki-67 findings 117 , and could be stratified as shown in Table 3 .
No randomized or prospective studies have compared different follow-up protocols after surgery for ACC. The following recommendations are based on selected retrospective series from specialized centres and expert opinion. Follow-up evaluation should include clinical and hormonal 18 FDG-PET. The first postoperative follow-up should be done within 3 months of surgery. Follow-up should then be conducted every 3 months for the next 2 years, every 4 months for patients at intermediate or high risk of recurrence, or every 6 months for patients with a low recurrence risk. After 5 years, follow-up should be every 6-12 months for up to 10 years. In case of doubt, hepatic MRI (with diffusion-weighted MRI) could be used to characterize small liver lesions more accurately.
Adjuvant mitotane treatment has become the standard treatment for many patients with ACC 118 -120 and is currently being addressed in an ongoing randomized trial.
Recommendation 20
The Local and/or metastatic recurrence occurs in up to 74 per cent of patients after surgery, even following R0 resection 121 . Local and/or metastatic recurrences usually occur within the first 2 postoperative years 68, 86, 122 , with a median interval between resection and first recurrence of approximately 1 year 86, 122 . Only a few studies have reported the results of surgical management of recurrent ACC 62 -64,86,108,123-128 .
Local recurrence
Approximately 20-60 per cent of reported recurrences are locoregional. The recurrence is isolated in one-quarter of cases 64, 85 . Whether adjuvant radiotherapy of the tumour bed can reduce the risk of local recurrence remains to be proven formally 85, 129, 130 . Patients with local recurrence are sometimes symptomatic because of mass symptoms and/or hormonal oversecretion. Less than half of the patients with local recurrence are amenable to radical R0 resection of the recurrent disease 86 . Only R0 resection of the locally recurrent disease provides a survival benefit. Laparoscopic resection should be contraindicated in the management of recurrent ACC. After reoperation, median progression-free survival is between 6 and 32 months 122, 124 , and survival is more favourable in patients with an initially long disease-free interval. Reoperation is also associated with improvement of symptoms in most patients 122 . The decision to offer reoperation should be balanced with the risk of morbidity (12-55 per cent) and mortality (0-4 per cent) associated with reoperation 108, 122, 126, 127, 131 . A third resection can be offered to patients with local recurrence after initial resection of local recurrence, especially if R0 resection is possible. Mitotane adjuvant treatment after resection of local recurrence could help reduce second recurrence, even though this remains controversial 122, 128 . If R0 resection of the locoregional recurrence is unlikely, neoadjuvant treatment should be discussed. Patients with early recurrence (within less than 6 months) are usually poor candidates for surgery because of their overall dismal prognosis.
Recommendation 21
Synchronous and metachronous metastatic ACC
Metastatic disease is a common feature in patients with ACC, with about one-third of patients having synchronous metastasis at diagnosis 70, 132 . More than half of the patients will develop distant metastases despite complete initial resection of the primary tumour 67, 133 . The overall 5-year survival rate in patients with metastatic disease is less than 20 per cent, with median survival between 6 and 20 months 65, 134 . The number of metastatic organs at the time of the first metastasis and a high mitotic rate (more than 20 per 50 high-power fields) are independent prognostic factors for patients with stage IV disease 134 . Nevertheless, metastatic ACC is a heterogeneous disease, and long survival has been reported following resection and repeated surgery 63, 64 . The number of patients with metastatic ACC referred for surgery in each centre remains low 124 .
Resection of metastatic ACC is rarely curative, but can be associated with prolonged survival. Surgery should be considered only if R0 resection is achievable at both the primary and metastatic sites, with low morbidity and mortality rates. The decision to operate on metastatic ACC should also include tumour criteria: disease-free interval of more than 1 year for metachronous metastasis 108, 125 ; low Ki-67 proliferation index of the primary lesion or metastasis, if available; young age at the time of the first metastasectomy 127 ; and favourable response to neoadjuvant chemotherapy 135 . Time to first recurrence after adrenalectomy and ENSAT T category of the primary tumour were associated with increased overall survival after pulmonary metastasectomy 126 . In selected patients, median survival and the 5-year survival rate from the time of first metastasectomy were 1.9-4.1 years and 29-41 per cent respectively 99, 125 . The recurrence of pulmonary or liver metastases should not exclude repeated surgical resection, if repeat R0 resection is achievable. Ablation techniques such as microwave or radiofrequency ablation can be combined with surgery to achieve R0 resection 136 . It is also important to note that patients with synchronous metastases are usually poor candidates for surgery because of their overall dismal prognosis.
Recommendation 22
The The benefit of R2 resection of the primary ACC in patients with unresectable metastatic or locally recurrent disease has not been well studied. Studies of other cancers, such as renal carcinoma 137 , cannot be extrapolated to ACC. In this setting, resection of primary ACC in the case of unresectable metastatic disease or palliative (R2) resection cannot be recommended. Patients with incomplete resection (R2 or debulking surgery) and patients not undergoing any surgery have similar progression-free survival 86 , even though anecdotal series have reported favourable outcome after surgery 122 . However, debulking surgery may be considered for large, symptomatic and/or oversecreting ACC resistant to medical treatment when at least 80 per cent of the tumour is removable with minimal/acceptable morbidity. 
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